Mechanism

How it works

ARA290 selectively binds to and activates the innate repair receptor (IRR), a heterodimer composed of the EPO receptor and the beta common receptor (βcR/CD131), distinct from the homodimeric EPO receptor responsible for red blood cell production. Activation of the IRR triggers downstream signaling cascades including PI3K/Akt and JAK2/STAT pathways that promote cell survival, reduce apoptosis, suppress NF-κB-mediated inflammation, and drive tissue repair. This mechanism selectively confers cytoprotective, neuroprotective, and anti-inflammatory effects without inducing erythropoietic or thrombotic activity.

Reported in research

Benefits

Reduction of small fiber neuropathy symptoms including pain, burning, and sensory loss
Anti-inflammatory and immunomodulatory effects relevant to sarcoidosis and related conditions
Neuroprotection and support of peripheral nerve repair and regeneration
Potential improvement in autonomic function, fatigue, and quality of life in neuropathic conditions

Context, not a prescription

Dosing

Typical range: 4 mg subcutaneously once daily (clinical trials); research protocols vary from 4–16 mg/day (Subcutaneous)
Cycle length: 4–28 weeks depending on indication and protocol
Half-life: ~3–4 hours

Safety

Side effects & contraindications

Possible side effects

Mild injection site reactions (redness, minor swelling)
Transient headache
Mild fatigue or dizziness
Nausea (uncommon)

Contraindications

Known hypersensitivity to ARA290 or EPO-derived peptides
Active malignancy (theoretical proliferative concern; insufficient data)
Pregnancy and breastfeeding (insufficient safety data)
Concurrent use of erythropoiesis-stimulating agents without medical supervision

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Possible reductions in burning or shooting nerve pain, improved sensation in affected areas, reduced systemic fatigue associated with inflammatory conditions, and potential improvements in autonomic symptoms like heart rate variability.

How it works

Imagine EPO is a Swiss Army knife. Most people only know about its blood-building blade. ARA290 is like pulling out just the 'repair tool' blade — it helps heal and calm down inflammation without opening any of the other functions you don't need.

When injected under the skin, ARA290 travels to nerves and inflamed tissues, where it binds to a special receptor that tells cells to survive, stop being inflamed, and start repairing. This is especially helpful in conditions where small nerve fibers are damaged or chronically irritated.

What to expect

Some users and clinical trial participants report subtle reductions in pain and improved sensation beginning within 2–4 weeks of daily use, with more noticeable changes often reported after 4–8 weeks.

Week 1: Peptide begins engaging the innate repair receptor. Minor injection site reactions may occur. Most people notice little difference yet.
Weeks 2–4: Anti-inflammatory effects begin accumulating. Some users report mild reduction in nerve pain intensity and improved sleep quality.
Weeks 4–8: More consistent improvements in neuropathic symptoms, sensory function, and energy levels may become apparent. Clinical trials show the greatest benefit in this window.

Good to know

Start with a lower dose to assess personal tolerance before advancing to the full research dose
Rotate injection sites to minimize local skin reactions

Staying safe

Minor redness or soreness at the injection site
Occasional mild headache after dosing

Avoid if you have:

People with active cancer or a recent cancer diagnosis
Pregnant or breastfeeding individuals
Anyone with a known allergy to EPO-related compounds

Overview

Quantitative improvements include reduced intraepidermal nerve fiber density loss (measured by skin punch biopsy), decreased scores on neuropathic pain scales (SFNSL, VAS), improved corneal nerve fiber length on confocal microscopy, reduced serum inflammatory markers (CRP, IL-6), and improvements in autonomic metrics including heart rate variability and sudomotor function.

How it works

Consider the EPO signaling system as a building with two entrances: the main 'hematopoietic' entrance (homodimeric EPOR) that controls blood cell factory operations, and a side 'repair and maintenance' entrance (the IRR heterodimer). Standard EPO opens both doors simultaneously. ARA290 is precision-engineered to have a key that only fits the side repair entrance, leaving the blood factory door completely locked — eliminating erythropoietic and prothrombotic liability while maximizing tissue-protective output.

Following subcutaneous administration, ARA290 achieves peak plasma concentrations within approximately 30–60 minutes with a reported half-life of 3–4 hours. IRR expression is upregulated in stressed or injured tissue, meaning the peptide exhibits a degree of injury-site specificity. In peripheral neurons and Schwann cells, IRR activation promotes axonal survival, reduces oxidative stress via Nrf2 pathway modulation, and supports remyelination. Systemically, ARA290 shifts the cytokine milieu toward an anti-inflammatory phenotype and has demonstrated reduction in corneal confocal microscopy-measured small fiber nerve density loss in sarcoidosis patients in double-blind trials.

Onset & timeline

Pharmacokinetically active within 30–60 minutes post-injection. Functional anti-inflammatory effects at the tissue level are demonstrable within days in preclinical models. In human clinical trials, statistically significant improvements in neuropathic pain and small fiber density were observed at 4 weeks, with progressive improvement through 28-week follow-up periods.

Days 1–3: ARA290 achieves Cmax within 30–60 minutes per dose. IRR occupancy in peripheral tissues begins immediately. NF-κB suppression detectable in preclinical models within 24 hours. Clinically, no perceptible changes expected at this stage.
Weeks 1–2: Accumulating anti-inflammatory effects manifest as modest reductions in pro-inflammatory cytokines. Early reports of reduced pain intensity in some subjects. Peripheral nerve microenvironment begins shifting toward pro-regenerative state with upregulation of neurotrophic factors.
Weeks 2–8: Peak clinical benefit window. Phase 2 data demonstrates significant improvements in SFNSL neuropathy scores, corneal nerve fiber length, and autonomic parameters. Intraepidermal nerve fiber density improvements measurable by biopsy. Systemic inflammatory markers trend downward. Some patients report sustained improvement beyond the active dosing period, consistent with durable nerve regeneration rather than purely symptomatic suppression.

Getting the most from it

Baseline CBC and CRP/ESR monitoring prior to and during extended cycles to detect any unexpected hematological or inflammatory shifts
In neuropathy protocols, use corneal confocal microscopy or skin punch biopsy at baseline and at 3-month intervals as objective outcome measures to titrate continued use
Avoid combining with erythropoiesis-stimulating agents (ESAs) due to theoretical receptor competition and additive cardiovascular risk

Common side effects

Injection site erythema and mild induration — reported in approximately 10–15% of participants in Phase 2 trials, typically self-resolving within 24 hours
Mild headache occurring in the first 1–2 weeks of dosing, likely related to peripheral vasodilatory effects downstream of IRR/βcR signaling

Mechanism of action

ARA290 is an 11-amino acid cyclic helix B surface peptide (HBSP) mimic of erythropoietin engineered to selectively bind the innate repair receptor (IRR), a heterodimeric complex of the erythropoietin receptor (EPOR) and the beta common receptor (βcR, CD131). Unlike homodimeric EPOR activation which drives erythropoiesis and can promote thrombosis or tumor growth, IRR activation primarily signals through PI3K/Akt, JAK2/STAT3, and MAPK/ERK pathways to produce cytoprotective, anti-apoptotic, and immunomodulatory effects. Critically, ARA290 suppresses NF-κB-driven pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β), promotes M2 macrophage polarization, and enhances small fiber nerve survival and regeneration — all without stimulating erythroid progenitor proliferation.

Following subcutaneous administration, ARA290 achieves peak plasma concentrations within approximately 30–60 minutes with a reported half-life of 3–4 hours. IRR expression is upregulated in stressed or injured tissue, meaning the peptide exhibits a degree of injury-site specificity. In peripheral neurons and Schwann cells, IRR activation promotes axonal survival, reduces oxidative stress via Nrf2 pathway modulation, and supports remyelination. Systemically, ARA290 shifts the cytokine milieu toward an anti-inflammatory phenotype and has demonstrated reduction in corneal confocal microscopy-measured small fiber nerve density loss in sarcoidosis patients in double-blind trials.

Pharmacodynamics

Pharmacokinetically active within 30–60 minutes post-injection. Functional anti-inflammatory effects at the tissue level are demonstrable within days in preclinical models. In human clinical trials, statistically significant improvements in neuropathic pain and small fiber density were observed at 4 weeks, with progressive improvement through 28-week follow-up periods.

Quantitative improvements include reduced intraepidermal nerve fiber density loss (measured by skin punch biopsy), decreased scores on neuropathic pain scales (SFNSL, VAS), improved corneal nerve fiber length on confocal microscopy, reduced serum inflammatory markers (CRP, IL-6), and improvements in autonomic metrics including heart rate variability and sudomotor function.

Timeline

Days 1–3: ARA290 achieves Cmax within 30–60 minutes per dose. IRR occupancy in peripheral tissues begins immediately. NF-κB suppression detectable in preclinical models within 24 hours. Clinically, no perceptible changes expected at this stage.
Weeks 1–2: Accumulating anti-inflammatory effects manifest as modest reductions in pro-inflammatory cytokines. Early reports of reduced pain intensity in some subjects. Peripheral nerve microenvironment begins shifting toward pro-regenerative state with upregulation of neurotrophic factors.
Weeks 2–8: Peak clinical benefit window. Phase 2 data demonstrates significant improvements in SFNSL neuropathy scores, corneal nerve fiber length, and autonomic parameters. Intraepidermal nerve fiber density improvements measurable by biopsy. Systemic inflammatory markers trend downward. Some patients report sustained improvement beyond the active dosing period, consistent with durable nerve regeneration rather than purely symptomatic suppression.

Comparisons

ARA290 (Cibinetide) — effectiveness Moderate, safety Good, cost $$$, Medium to use
Thymosin Alpha-1 — effectiveness Moderate, safety Excellent, cost $$$, Medium to use
BPC-157 — effectiveness High, safety Good, cost $$, Medium to use

Adverse effects

Common:

Injection site erythema and mild induration — reported in approximately 10–15% of participants in Phase 2 trials, typically self-resolving within 24 hours
Mild headache occurring in the first 1–2 weeks of dosing, likely related to peripheral vasodilatory effects downstream of IRR/βcR signaling

Rare:

Transient hypertension has been observed in a small subset of subjects, though ARA290 lacks the sustained vasopressor effect of full-length EPO (incidence <5% in trials)
Potential theoretical concern of promoting survival in pre-malignant cells expressing IRR, though no oncogenic signal has been demonstrated in clinical studies to date

Contraindications & risk mitigation

Contraindicated in:

Individuals with myeloproliferative disorders or polycythemia vera — risk of cross-reactivity with hematopoietic pathways, however unlikely
Patients with active autoimmune conditions on complex immunosuppressive regimens — immunomodulatory effects may interact unpredictably
Individuals with known βcR (CD131) pathway dysregulation or IL-3/GM-CSF receptor mutations

Baseline CBC and CRP/ESR monitoring prior to and during extended cycles to detect any unexpected hematological or inflammatory shifts
In neuropathy protocols, use corneal confocal microscopy or skin punch biopsy at baseline and at 3-month intervals as objective outcome measures to titrate continued use
Avoid combining with erythropoiesis-stimulating agents (ESAs) due to theoretical receptor competition and additive cardiovascular risk

Qué hace

Possible reductions in burning or shooting nerve pain, improved sensation in affected areas, reduced systemic fatigue associated with inflammatory conditions, and potential improvements in autonomic symptoms like heart rate variability.

Cómo funciona

Imagine EPO is a Swiss Army knife. Most people only know about its blood-building blade. ARA290 is like pulling out just the 'repair tool' blade — it helps heal and calm down inflammation without opening any of the other functions you don't need.

When injected under the skin, ARA290 travels to nerves and inflamed tissues, where it binds to a special receptor that tells cells to survive, stop being inflamed, and start repairing. This is especially helpful in conditions where small nerve fibers are damaged or chronically irritated.

Qué esperar

Some users and clinical trial participants report subtle reductions in pain and improved sensation beginning within 2–4 weeks of daily use, with more noticeable changes often reported after 4–8 weeks.

Week 1: Peptide begins engaging the innate repair receptor. Minor injection site reactions may occur. Most people notice little difference yet.
Weeks 2–4: Anti-inflammatory effects begin accumulating. Some users report mild reduction in nerve pain intensity and improved sleep quality.
Weeks 4–8: More consistent improvements in neuropathic symptoms, sensory function, and energy levels may become apparent. Clinical trials show the greatest benefit in this window.

Bueno saber

Start with a lower dose to assess personal tolerance before advancing to the full research dose
Rotate injection sites to minimize local skin reactions

Manteniéndose seguro

Minor redness or soreness at the injection site
Occasional mild headache after dosing

Evitar si tienes:

People with active cancer or a recent cancer diagnosis
Pregnant or breastfeeding individuals
Anyone with a known allergy to EPO-related compounds

Descripción general

Quantitative improvements include reduced intraepidermal nerve fiber density loss (measured by skin punch biopsy), decreased scores on neuropathic pain scales (SFNSL, VAS), improved corneal nerve fiber length on confocal microscopy, reduced serum inflammatory markers (CRP, IL-6), and improvements in autonomic metrics including heart rate variability and sudomotor function.

Cómo funciona

Consider the EPO signaling system as a building with two entrances: the main 'hematopoietic' entrance (homodimeric EPOR) that controls blood cell factory operations, and a side 'repair and maintenance' entrance (the IRR heterodimer). Standard EPO opens both doors simultaneously. ARA290 is precision-engineered to have a key that only fits the side repair entrance, leaving the blood factory door completely locked — eliminating erythropoietic and prothrombotic liability while maximizing tissue-protective output.

Following subcutaneous administration, ARA290 achieves peak plasma concentrations within approximately 30–60 minutes with a reported half-life of 3–4 hours. IRR expression is upregulated in stressed or injured tissue, meaning the peptide exhibits a degree of injury-site specificity. In peripheral neurons and Schwann cells, IRR activation promotes axonal survival, reduces oxidative stress via Nrf2 pathway modulation, and supports remyelination. Systemically, ARA290 shifts the cytokine milieu toward an anti-inflammatory phenotype and has demonstrated reduction in corneal confocal microscopy-measured small fiber nerve density loss in sarcoidosis patients in double-blind trials.

Inicio y cronología

Pharmacokinetically active within 30–60 minutes post-injection. Functional anti-inflammatory effects at the tissue level are demonstrable within days in preclinical models. In human clinical trials, statistically significant improvements in neuropathic pain and small fiber density were observed at 4 weeks, with progressive improvement through 28-week follow-up periods.

Days 1–3: ARA290 achieves Cmax within 30–60 minutes per dose. IRR occupancy in peripheral tissues begins immediately. NF-κB suppression detectable in preclinical models within 24 hours. Clinically, no perceptible changes expected at this stage.
Weeks 1–2: Accumulating anti-inflammatory effects manifest as modest reductions in pro-inflammatory cytokines. Early reports of reduced pain intensity in some subjects. Peripheral nerve microenvironment begins shifting toward pro-regenerative state with upregulation of neurotrophic factors.
Weeks 2–8: Peak clinical benefit window. Phase 2 data demonstrates significant improvements in SFNSL neuropathy scores, corneal nerve fiber length, and autonomic parameters. Intraepidermal nerve fiber density improvements measurable by biopsy. Systemic inflammatory markers trend downward. Some patients report sustained improvement beyond the active dosing period, consistent with durable nerve regeneration rather than purely symptomatic suppression.

Cómo aprovecharlo al máximo

Baseline CBC and CRP/ESR monitoring prior to and during extended cycles to detect any unexpected hematological or inflammatory shifts
In neuropathy protocols, use corneal confocal microscopy or skin punch biopsy at baseline and at 3-month intervals as objective outcome measures to titrate continued use
Avoid combining with erythropoiesis-stimulating agents (ESAs) due to theoretical receptor competition and additive cardiovascular risk

Efectos secundarios comunes

Injection site erythema and mild induration — reported in approximately 10–15% of participants in Phase 2 trials, typically self-resolving within 24 hours
Mild headache occurring in the first 1–2 weeks of dosing, likely related to peripheral vasodilatory effects downstream of IRR/βcR signaling

Mecanismo de acción

ARA290 is an 11-amino acid cyclic helix B surface peptide (HBSP) mimic of erythropoietin engineered to selectively bind the innate repair receptor (IRR), a heterodimeric complex of the erythropoietin receptor (EPOR) and the beta common receptor (βcR, CD131). Unlike homodimeric EPOR activation which drives erythropoiesis and can promote thrombosis or tumor growth, IRR activation primarily signals through PI3K/Akt, JAK2/STAT3, and MAPK/ERK pathways to produce cytoprotective, anti-apoptotic, and immunomodulatory effects. Critically, ARA290 suppresses NF-κB-driven pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β), promotes M2 macrophage polarization, and enhances small fiber nerve survival and regeneration — all without stimulating erythroid progenitor proliferation.

Following subcutaneous administration, ARA290 achieves peak plasma concentrations within approximately 30–60 minutes with a reported half-life of 3–4 hours. IRR expression is upregulated in stressed or injured tissue, meaning the peptide exhibits a degree of injury-site specificity. In peripheral neurons and Schwann cells, IRR activation promotes axonal survival, reduces oxidative stress via Nrf2 pathway modulation, and supports remyelination. Systemically, ARA290 shifts the cytokine milieu toward an anti-inflammatory phenotype and has demonstrated reduction in corneal confocal microscopy-measured small fiber nerve density loss in sarcoidosis patients in double-blind trials.

Farmacodinamia

Pharmacokinetically active within 30–60 minutes post-injection. Functional anti-inflammatory effects at the tissue level are demonstrable within days in preclinical models. In human clinical trials, statistically significant improvements in neuropathic pain and small fiber density were observed at 4 weeks, with progressive improvement through 28-week follow-up periods.

Quantitative improvements include reduced intraepidermal nerve fiber density loss (measured by skin punch biopsy), decreased scores on neuropathic pain scales (SFNSL, VAS), improved corneal nerve fiber length on confocal microscopy, reduced serum inflammatory markers (CRP, IL-6), and improvements in autonomic metrics including heart rate variability and sudomotor function.

Cronología

Days 1–3: ARA290 achieves Cmax within 30–60 minutes per dose. IRR occupancy in peripheral tissues begins immediately. NF-κB suppression detectable in preclinical models within 24 hours. Clinically, no perceptible changes expected at this stage.
Weeks 1–2: Accumulating anti-inflammatory effects manifest as modest reductions in pro-inflammatory cytokines. Early reports of reduced pain intensity in some subjects. Peripheral nerve microenvironment begins shifting toward pro-regenerative state with upregulation of neurotrophic factors.
Weeks 2–8: Peak clinical benefit window. Phase 2 data demonstrates significant improvements in SFNSL neuropathy scores, corneal nerve fiber length, and autonomic parameters. Intraepidermal nerve fiber density improvements measurable by biopsy. Systemic inflammatory markers trend downward. Some patients report sustained improvement beyond the active dosing period, consistent with durable nerve regeneration rather than purely symptomatic suppression.

Comparaciones

ARA290 (Cibinetide) — efectividad Moderate, seguridad Good, costo $$$, Medium de usar
Thymosin Alpha-1 — efectividad Moderate, seguridad Excellent, costo $$$, Medium de usar
BPC-157 — efectividad High, seguridad Good, costo $$, Medium de usar

Efectos adversos

Comunes:

Injection site erythema and mild induration — reported in approximately 10–15% of participants in Phase 2 trials, typically self-resolving within 24 hours
Mild headache occurring in the first 1–2 weeks of dosing, likely related to peripheral vasodilatory effects downstream of IRR/βcR signaling

Raros:

Transient hypertension has been observed in a small subset of subjects, though ARA290 lacks the sustained vasopressor effect of full-length EPO (incidence <5% in trials)
Potential theoretical concern of promoting survival in pre-malignant cells expressing IRR, though no oncogenic signal has been demonstrated in clinical studies to date

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Individuals with myeloproliferative disorders or polycythemia vera — risk of cross-reactivity with hematopoietic pathways, however unlikely
Patients with active autoimmune conditions on complex immunosuppressive regimens — immunomodulatory effects may interact unpredictably
Individuals with known βcR (CD131) pathway dysregulation or IL-3/GM-CSF receptor mutations

Baseline CBC and CRP/ESR monitoring prior to and during extended cycles to detect any unexpected hematological or inflammatory shifts
In neuropathy protocols, use corneal confocal microscopy or skin punch biopsy at baseline and at 3-month intervals as objective outcome measures to titrate continued use
Avoid combining with erythropoiesis-stimulating agents (ESAs) due to theoretical receptor competition and additive cardiovascular risk

Reference data

Specifications

Molecular formula: C52H73N13O15S
Molecular weight: 1180.28 g/mol
Half-life: ~3–4 hours
Route: Subcutaneous
Cycle length: 4–28 weeks depending on indication and protocol
Storage: Store lyophilized powder at -20°C; reconstituted solution refrigerated at 2–8°C and used within 72 hours. Protect from light and repeated freeze-thaw cycles.
Legal status: Research compound; not FDA-approved for any indication. Investigational status in the EU (orphan designation for sarcoidosis-associated small fiber neuropathy). Legal for research purposes in most jurisdictions; not approved for human therapeutic use outside clinical trials.

FAQ

Common questions

How does ARA290's selectivity for the IRR versus the homodimeric EPOR translate to its clinical safety advantage over full-length EPO?

Full-length EPO activates both the homodimeric EPOR (erythropoiesis, thrombosis risk, potential tumor promotion) and the heterodimeric IRR (tissue repair, neuroprotection). ARA290's structural design — based on the helix B surface of EPO — has minimal affinity for homodimeric EPOR (reported >10,000-fold selectivity for IRR in binding assays) while retaining full IRR agonist activity. This eliminates erythrocytosis, hypertension, and the thrombotic adverse event profile that limits therapeutic EPO use, as confirmed across Phase 1 and Phase 2 trials showing no change in hematocrit or hemoglobin.

What is the current regulatory and clinical development status of ARA290?

Araim Pharmaceuticals developed ARA290 through Phase 2 trials including a double-blind RCT published in Molecular Medicine (2016) and subsequent sarcoidosis-specific trials published in Chest (2019). It received EU Orphan Drug Designation for sarcoidosis-associated small fiber neuropathy. As of available data, it has not progressed to Phase 3 registration trials and remains an investigational compound without regulatory approval in any jurisdiction for clinical use.

What is the evidence level?

This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.

Research

Research & sources

Limited human

Current evidence for ARA290 (Cibinetide) is rated as Limited human data. Limited human data is available.

1. ARA290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Produces Long-term Pain Reduction in Patients with Small Fiber Neuropathy (2016) — Molecular Medicine, PMID: 27261971
2. Cibinetide for the Treatment of Sarcoidosis-Associated Small Fiber Neuropathy: A Randomized, Placebo-Controlled, Phase 2 Trial (2019) — Chest, PMID: 31260672
3. The Innate Repair Receptor: A Novel Paradigm for Cytoprotection and End-Organ Injury (2013) — Journal of Internal Medicine, PMID: 23072442
4. Erythropoietin and Its Derivatives: From Tissue Protection to Immune Regulation (2015) — Cellular and Molecular Life Sciences, PMID: 25673591

Explore

Often discussed alongside

BPC-157 · healing TB-500 · healing LL-37 · immune Thymosin Alpha-1 · immune